$TP

Ticketplus Ltd. (AMEX:TP) acquired Argentine ticketing company Autoentrada S.A., its first acquisition post-IPO. The deal strengthens Ticketplus's presence in Argentina, with Autoentrada operating in 18 provinces. Financial terms were not disclosed. Ticketplus expects the acquisition to capture more value per ticket but not materially impact 2026 results. Autoentrada's founder will join Ticketplus as Country Manager for Argentina.

Ticketplus Ltd. shares rose after Roth Capital Partners initiated coverage with a buy rating. The stock's average target price is $13.40, with a spread of +55.15% from the last close of $8.64. Analysts' consensus is buy, with two analysts covering the stock.

Ticketplus Ltd. (TP) shares rose on Monday following the expiration of its quiet period. Roth Capital initiated coverage with a Buy rating, according to the report. The Latin American smart ticketing platform's stock gained on the news.

Analysts upgraded Deere (DE) to Outperform with a $800 target, citing strong North American demand. Abercrombie & Fitch (ANF) was upgraded to Buy with a $162 target after Q2 earnings beat. Agco (AGCO) upgraded to Outperform with a $150 target, expecting 2027 volume recovery. Kaiser Aluminum (KALU) upgraded to Buy with a $184 target. Stag Industrial (STAG) upgraded to Outperform. PG&E (PCG) downgraded by Wells Fargo and BMO. Mizuho downgraded PG&E, Sempra Energy (SRE), and Edison International (E

Wall Street analysts made several calls: Baird upgraded AGCO to $150 and Deere to $800, while Mizuho downgraded Edison International and Sempra Energy. Evercore ISI initiated Lumentum at Outperform with a $1,100 target, and Roth Capital started Ticketplus at Buy with a $14 target. Markets closed lower Friday due to Fed rate-hike concerns, with Treasury yields rising and major indices down.

Analysts initiated coverage on five companies: Evercore ISI rated Lumentum (LITE) Outperform with $1,100 target; BTIG rated Smith & Nephew (SNN) Neutral; Morgan Stanley rated Attovia (ATTO) Overweight with $39 target; Roth Capital rated Ticketplus (TP) Buy with $14 target; Stifel rated Braveheart Bio (BRVE) Buy with $45 target.

The page is a roundup of personal finance, ETF, and stock-pick pieces plus IPO and market-mover items. It notes Latigo Biotherapeutics priced an IPO at $18 raising $345.6M, BlossomHill priced at $16 raising $150M, and Ticketplus priced at $8 raising $15M. It also lists big gainers like Airbnb and losers like Trade Desk.

Ticketplus Ltd. (TP) priced its Nasdaq IPO at $8 per share, raising about $15 million by selling 1.875 million shares, according to the IPO pricing details. The offering is led by Roth Capital Partners with Bancroft Capital and MDB Capital, marking the company’s Nasdaq debut.

Ticketplus Ltd. priced its IPO of 1,875,000 ordinary shares at $8.00 each on NYSE American, according to the company. The deal is expected to raise about $15 million in gross proceeds, with a 45-day option for up to 281,250 additional shares. Shares are set to trade under ticker TP on Aug. 7, 2026.

Air France-KLM and Lufthansa Group submitted binding bids to buy 44.9% to 49.9% of TAP Air Portugal from Portugal’s state holding Parpública, without disclosing bid values. Both said they would preserve Lisbon as a hub and expand connectivity, including transatlantic routes. Air France-KLM cited MRO investment plans supported by Delta Air Lines; Lufthansa said TAP is already in Star Alliance and Lisbon would focus on South America.